Bacteria Biohybrid Oral Vaccines for Colorectal Cancer Treatment Reduce Tumor Growth and Increase Immune Infiltration

Authors: M. Naciute, T. Kiwitt, R.A. Kemp,and S. Hook

Journal: Vaccine


Publication - Abstract

September 15, 2021

Therapeutic peptide cancer vaccines are known to have limited therapeutic effects due to the low immunogenicity of peptides in its composition. In hopes of increasing this therapeutic window, researchers from the Hook Group at the University of Otago School of Pharmacy published an article that investigated the potential of bacteria biohybrid oral vaccines to treat colorectal cancer using liposomal formulations and w/o/w emulsions. With the help of the NanoAssemblr ®’s microfluidic mixing technology, authors were able to synthesize liposomes E. coli co-encapsulated with tumor antigens, such as, CD8 epitope, CD4 epitope and AH1td peptide with adjuvants like Pam2Cys. The application of these biohybrid vaccines to murine bone marrow derived dendritic cells (BMDC) in vitro and to BALB/c mouse models of colorectal cancer in vivo illustrated how liposome-bacteria biohybrids induced a more robust uptake within cells due to its cationic charge and tunable droplet size when compared to double emulsion bacteria biohybrids. Results of this paper highlight that delivery of a bacterium rather than peptide antigens alone are capable of inducing higher immunostimulatory effects due to certain bacterial properties, such as, PAMPs, and lipopolysaccharide components. In the grand scheme, this paper serves as an essential cornerstone for further developments in liposomal formulations that foster a more stable conjugation in bacteria biohybrid vaccines to further accelerate the synthesis of effective anti-cancer therapeutics and enhancement of vaccine delivery.

Advanced Search

  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads

related content

Publication - Abstract

Lipid-based nanobiomaterials as liposomes and lipid nanoparticles (LNPs) are the most widely used nanocarriers for drug delivery systems (DDSs). Extracellular vesicles (EVs) and exosomes are also expected to be applied as DDS nanocarriers. The perf...

Read More

Publication - Abstract

Glucosamine-NISV Delivers Antibody Across the Blood-brain Barrier: Optimization for Treatment of Encephalitic Viruses

S. Woods, L.M. O'Brien, W. Butcher, J.E. Preston, A.R. Georgian, E.D. Williamson, F.J. Salguero, F. Modino, N.J. Abbott, C.W. Roberts and R.V. D'Elia

The field of brain drug delivery faces many challenges that hinder development and testing of novel therapies for clinically important central nervous system disorders. Chief among them is how to deliver large biologics across the highly restrictive blood-brain barrier. Non-ionic...
Read More

Sign Up and Stay Informed
Sign up today to automatically receive new Cytiva, formerly Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.